We list the best content calendar software, to make it simple and easy to better plan and schedule your content. Scheduling is essential for every person whose work revolves around publishing ...

Some of China’s senior doctors are raising concern over the quality of domestic generic medicines that have largely replaced western brand-name drugs at hospitals, amid a rare public backlash ...

A U.S. appeals court has lifted a temporary halt it imposed on the launch of a generic version of Novartis's (NYSE:NVS) top-selling cardiac drug Entresto. The U.S. Court of Appeals for the ...

The launch of a generic version of Novartis's (NYSE:NVS) blockbuster cardiac drug Entresto has reportedly been temporarily blocked by a federal appeals court as it considers the drugmaker's ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday. The U.S. Court ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

CVS says their clients’ specialty drug spend increased by 3.7% (PDF) for the 2023 calendar year, roughly inline with inflation. The company says the FTC cherry-picked specialty generic outliers ...

which it says focuses on pharmacy benefit managers’ influence over specialty generic drugs, “including significant price markups by PBMs for cancer, HIV, and a variety of other critical drugs.” ...

Caremark said the agency “cherry-picked specialty generic outliers,” adding it is “inappropriate and misleading to draw broad conclusions” from the data. The company also notes that ...

Teva cannot market its generic version of Firdapse in the U.S. before February 25, 2035, unless specific conditions arise. Ongoing Firdapse patent litigation continues against Hetero and Lupin ...